Bioventus Inc. (BVS) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

20/25

Growth 5 Margin 5 Expansion 5 Platform 1 Financial 4

latest quarter score

Earnings Reports

20
BioVentus (BVS) Q2 2026: Net Leverage Falls Below 2x as Pain Treatments Drive Growth and Strategic Review Launches
August 05, 2026
18
BioVentus (BVS) Q1 2026: EBITDA Margin Expands 260bps as Growth Investments Ramp
May 06, 2026
22
BioVentus (BVS) Q4 2025: EBITDA Margin Expands 490bps, Fueling Growth Driver Investment
March 05, 2026
18
BioVentus (BVS) Q3 2025: Margin Expands 220bps as Portfolio Shift Drives Profitable Growth
November 04, 2025
22
BioVentus (BVS) Q2 2025: PNS Launch Targets $100M+ Revenue as R&D Ramps
August 06, 2025
22
BioVentus (BVS) Q1 2025: Duralane Drives Double-Digit Growth, Setting Stage for Second-Half Acceleration
July 06, 2025
20
BioVentus (BVS) Q4 2024: Surgical Solutions and Pain Treatments Drive 13.5% Revenue Growth
March 11, 2025
BioVentus (BVS) Q3 2024: 15% Revenue Growth Extends Double-Digit Streak, Margin Expansion in Focus
November 05, 2024
BioVentus (BVS) Q2 2024: Organic Growth Accelerates to 14% as Core Portfolio Outpaces Market
August 06, 2024
BioVentus (BVS) Q1 2024: EBITDA Margin Surges 300bps as HA and Surgical Outperform
May 07, 2024
BioVentus (BVS) Q4 2023: Pain Treatments Surge 23% as Turnaround Accelerates
March 12, 2024

Browse all companies